HBI Stock Overview
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Harvard Bioscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.40 |
| 52 Week High | US$5.65 |
| 52 Week Low | US$3.40 |
| Beta | 1.45 |
| 1 Month Change | -10.53% |
| 3 Month Change | -18.66% |
| 1 Year Change | -32.67% |
| 3 Year Change | -40.87% |
| 5 Year Change | -1.36% |
| Change since IPO | 13.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| HBI | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -11.5% | -4.6% | 1.8% |
| 1Y | -32.7% | -8.0% | 2.2% |
Return vs Industry: HBI underperformed the German Life Sciences industry which returned -8% over the past year.
Return vs Market: HBI underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| HBI volatility | |
|---|---|
| HBI Average Weekly Movement | 8.1% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HBI's share price has been volatile over the past 3 months.
Volatility Over Time: HBI's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1901 | 404 | Jim Green | www.harvardbioscience.com |
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems.
Harvard Bioscience, Inc. Fundamentals Summary
| HBI fundamental statistics | |
|---|---|
| Market cap | €151.12m |
| Earnings (TTM) | -€3.20m |
| Revenue (TTM) | €105.02m |
1.4x
P/S Ratio-47.3x
P/E RatioIs HBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HBI income statement (TTM) | |
|---|---|
| Revenue | US$112.25m |
| Cost of Revenue | US$45.86m |
| Gross Profit | US$66.39m |
| Other Expenses | US$69.81m |
| Earnings | -US$3.41m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.079 |
| Gross Margin | 59.15% |
| Net Profit Margin | -3.04% |
| Debt/Equity Ratio | 50.0% |
How did HBI perform over the long term?
See historical performance and comparison